Menu
Patiro is a global patient recruitment company founded in Denmark in 2014. We connect patients with clinical trials through a combination of global reach, hyper-local medical teams, and digital recruitment strategies. We work with sponsors, CROs, and clinical sites across the full patient journey, from outreach and pre-screening through to enrollment and retention.
Patiro is headquartered in Aalborg, Denmark, and operates globally across more than 44 countries.
Patiro works with pharmaceutical sponsors, biotechnology companies, CROs, and site management organisations across the full spectrum of clinical trial phases and therapeutic areas. Previous clients include AstraZeneca, Biogen, Bristol Myers Squibb, Amgen, and Horizon.
Patiro has worked with some of the world's leading pharmaceutical and biotechnology companies, including Bristol Myers Squibb, AstraZeneca, Biogen, Horizon, and Amgen, among others. We work with both large global sponsors and smaller biotechnology companies across a wide range of therapeutic areas and geographies.
What sets Patiro apart is the combination of global infrastructure with hyper-local medical teams who understand their communities and can pre-screen patients with cultural and clinical precision. We offer a pay-only-per-enrolled-patient model where you only pay when a patient is enrolled, and not before that. Sponsors can engage us for our full-service solutions for the full patient journey or for specific functions within an existing setup, which for example can be patient recruitment, site management or study branding only. Our AI Voice Agent, Ava, supports pre-screening at scale alongside our medical teams. And our proprietary Patient Management Platform gives sponsors and sites real-time visibility across the entire process, from first patient contact through to randomization, with customizable reporting that is built around what each program needs. Based on case studies, our approach has delivered 40% faster recruitment timelines and a 65% reduction in patient attrition rates.
Patiro offers full-service patient recruitment covering the entire patient journey from outreach to enrollment and retention. We also offer standalone services including patient recruitment only, site support only, and study branding only. Sponsors and CROs can engage us for the full package or for the specific components that complement their existing setup.
Full-service patient recruitment means Patiro manages the entire process from initial patient outreach through pre-screening, referral, site support, and retention. It includes digital advertising, community outreach, study branding, patient management, and ongoing site communication, so sponsors have a single accountable partner across the entire recruitment lifecycle.
Yes. Patiro can provide patient referrals only, site support only, or study branding only, depending on what a sponsor or CRO needs. Our services are designed to integrate with existing infrastructure rather than replace it where that makes more sense.
Yes. Patiro can operate as a functional service provider, embedding specific capabilities into a sponsor or CRO's existing framework. Whether that means providing pre-screened patient referrals, managing site communications, or supporting study branding, we can scope our involvement to fit the operational model already in place.
Study branding involves creating a distinct visual and communicative identity for a clinical trial, including custom logos, naming, digital and print materials, and patient-facing messaging. A well-branded study improves patient recognition, trust, and engagement, which directly supports recruitment and retention outcomes.
Patiro's proprietary Patient Management Platform gives sponsors and sites real-time visibility across the full trial process, from patient identification to randomization. It provides a clear overview of where patients are coming from, which referral sources are performing best, and how each site is tracking. The platform includes customizable reporting tools that support data-driven decisions on enrollment optimization, site performance, and protocol amendment planning. It reduces administrative burden for sites and allows staff to focus on patient care rather than administrative tasks and paperwork.
Patiro provides sites with access to our proprietary Patient Management Platform, which gives real-time visibility across the full trial process from patient identification through to randomization. Sites can track patient details, monitor referral performance, and access customizable reporting tools to support data-driven enrollment decisions. Patiro is also integrated with IQVIA's One Home for Sites, giving sites a connected technology environment that reduces administrative burden and allows staff to focus on patient care and trial success.
Ava is Patiro's AI Voice Agent, purpose-built to work alongside our global medical pre-screening team. Ava manages both inbound and outbound calls, guides patients through structured study questionnaires, and supports pre-screening at scale. She is fully embedded in study workflows and delivers consistent, clinically structured support for both sites and patients worldwide. Ava does not work independently - she is directly supported by Patiro's global medical team throughout the process.
Yes. Patiro uses AI and algorithmic tools to optimize patient recruitment performance, which includes targeting, outreach, and lead quality. Patiro also operates Ava, our proprietary AI Voice Agent purpose-built for clinical trial pre-screening. Ava manages inbound and outbound calls, guides patients through structured study questionnaires, and supports pre-screening at scale. Ava works alongside and is directly supported by Patiro's global medical team and ensures clinical precision throughout the process.
Patiro offers flexible payment models that can be adapted to the needs of the study. One model we offer is payment only per enrolled patient, which means sponsors do not pay until a patient has been successfully enrolled in the trial. This model aligns our incentives directly with your enrollment goals and removes financial risk from the patient recruitment process.
Yes. Patiro offers a pay-only-per-enrolled-patient model, meaning sponsors are not charged until a patient has been successfully enrolled in the trial. This model directly aligns Patiro's incentives with the sponsor's enrollment goals and reduces financial risk in the recruitment process. Payment models can be adapted to the needs of the study, so we encourage sponsors to get in touch to discuss what works best for their situation.
Yes. Patiro offers a no cure no pay model where sponsors are charged only when a patient is confirmed as enrolled. This gives sponsors budget certainty and makes sure accountability is tied directly to results.
There is no fixed minimum study size or budget to work with Patiro. The right fit depends on the study, the indication, and what is needed. We recommend getting in touch with our team to discuss your specific study and find out whether Patiro is the right match.
Patiro has recruited patients across more than 44 countries spanning five continents. Countries where we have prior experience include Ireland, Norway, Croatia, Ukraine, India, Finland, Turkey, Portugal, Chile, Australia, Argentina, Austria, Brazil, Canada, Czech Republic, Belgium, Denmark, Germany, Greece, France, Italy, Israel, Netherlands, Mexico, Poland, Puerto Rico, Russia, Spain, Sweden, Switzerland, United Kingdom, and United States, among others. We are actively open to supporting trials in new markets and geographies beyond this list.
Yes. Patiro is built for multinational and global trials. Our global network of hyper-local medical teams means we can coordinate recruitment across multiple countries at the same time while maintaining local cultural and regulatory precision in each trial location.
Patiro has operated across North America, South America, Europe, Asia, and Oceania. Our global network of hyper-local medical teams is built to reach patients wherever they are, and we are actively open to supporting trials in new markets when a study requires it. Get in touch and we will tell you quickly what is possible.
Patiro communicates with sponsors and CROs in English. For patient-facing recruitment, our local pre-screeners speak the language of the market they operate in, and all patient outreach, recruitment materials, and pre-screening calls are conducted in the local language. This ensures patients can engage with the process naturally and comfortably regardless of where they live.
Patiro recruits across a comprehensive range of therapeutic areas including oncology, rare diseases, neurology (including CNS), psychiatry, endocrinology (including obesity, weight loss, and GLP-1 trials), metabolic diseases, cardiovascular, immunology, infectious diseases, pulmonology, gastroenterology (including hepatology), dermatology, ophthalmology, hematology, urology, pediatrics, obstetrics and gynecology, rheumatology, and genetic disorders, among others.
Yes. Rare disease recruitment is one of Patiro's core areas of expertise. We have over a decade of experience identifying and reaching patients across more than 2,000 conditions, including ultra-rare indications where conventional recruitment methods are insufficient.
Yes. Patiro supports recruitment for investigational medicines, medical devices, and medical procedures. We adapt our recruitment approach to the specific requirements of each trial type.
Yes. Patiro supports clinical trial recruitment across Phase 1 through Phase 4 studies and we adapt our approach to the specific enrollment goals, eligibility complexity, and timelines associated with each phase.
Yes. Patiro has experience recruiting for pediatric clinical trials. Pediatric recruitment requires particular sensitivity given the involvement of parents or guardians in the consent process, strict age-specific eligibility criteria, and the additional ethical considerations that apply to trials involving children. Our local medical teams are experienced in navigating these requirements and communicating appropriately with families throughout the recruitment and pre-screening process.
Patiro uses a multi-channel approach to reach potential participants. This may include social media advertising, search advertising, email marketing, display advertising, programmatic advertising, community outreach, patient advocacy networks, and our existing patient database. Outreach is tailored to the specific indication, geography, and patient profile required by each study.
Potential candidates are pre-screened and help up against the trial's inclusion and exclusion criteria before being referred to a clinical site. Pre-screening is conducted by Patiro's local medical teams or by Ava, our AI Voice Agent, for patients who prefer that option or find it more comfortable. Both approaches follow the same structured, clinically informed process. This ensures that sites receive only qualified and motivated referrals, which protects site time and reduces screen failure rates.
Screen failure is almost always a pre-screening problem. When candidates are not properly assessed against inclusion and exclusion criteria before being referred, sites spend time on patients who were never going to qualify. At Patiro, our pre-screening process is conducted by local medical teams or by Ava, our AI Voice Agent, screening every candidate against the study criteria before anyone at a site sees them. This means sites receive qualified and motivated referrals. That is how screen failure gets reduced.
Patient recruitment outreach can begin once countries, sites, and key study parameters are confirmed. The exact timeline depends on the study, the indication, and the markets involved. We work to move as quickly as the regulatory and operational framework allows.
Patiro's retention support includes structured patient follow-up, communication timed to the most demanding phases of the trial, logistical support such as travel assistance, and decentralized trial elements where appropriate. Our approach to patient retention has contributed to a 65% reduction in patient dropout rates based on case studies.
Patiro addresses diversity and inclusion in patient recruitment through the structure of how we recruit. Our hyper-local medical teams operate within communities, which means outreach is conducted in local languages by people who understand cultural context, trust barriers, and how to communicate with underrepresented groups in a way that feels relevant rather than generic. We use multilingual materials, community partnerships, and indication-specific outreach strategies to improve reach into populations that standard digital advertising often misses.
Based on case studies, Patiro has achieved 100% global regulatory approvals, 40% faster patient recruitment timelines, and a 65% reduction in patient dropout rates.
Yes, Patiro supports both fully decentralized and hybrid trial designs. Our recruitment and pre-screening approach adapts to the format of the study, whether participation is fully remote, hybrid, or site-based, which ensures that patients understand what the trial involves and can genuinely commit to it before referral.
Yes. Patiro is ISO 27001 certified, HIPAA compliant, and GDPR compliant. We conduct regular security audits and penetration testing to maintain the highest standards of data security across all geographic areas we operate in.
Patiro handles patient data in accordance with GDPR, HIPAA, and applicable local data protection regulations in every country where we operate. Data is collected only for the purposes of the clinical trial and is shared with research sites only with patient consent.
The first step is getting in touch with our team to discuss your study. You can reach us at hello@patiro.com or by scheduling a call through our website. We will discuss your indication, geography, timelines, and recruitment goals to determine how Patiro can best support your trial.
Patiro works with both sponsors and CROs. We are experienced in integrating into existing CRO-managed programs and can align with whatever governance and reporting structure is already in place.
Yes. Patiro can be brought in at any stage of a trial and this includes studies that are already underway but are behind on enrollment. We have experience with rescue studies and experience helping recruitment for trials that have stalled or underperformed against the initial projections.